一分钟看懂
这是一项关于胃癌的I 期研究，登记的药物或干预包括ASP2138；Pembrolizumab；Oxaliplatin；Leucovorin；Fluorouracil；Ramucirumab；Paclitaxel；Irinotecan；Capecitabine，当前状态为招募中。登记地点显示中国广州、郑州、武汉、上海等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
ASP2138；Pembrolizumab；Oxaliplatin；Leucovorin；Fluorouracil；Ramucirumab；Paclitaxel；Irinotecan；Capecitabine · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
- Henan Cancer Hospital · 郑州
- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology · 武汉
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · 上海
- The First Affiliated Hospital, College of Medicine, Zhejiang University · 杭州
公开的入选条件
- * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF).
- * Female participant is not pregnant, confirmed by serum pregnancy test \&vmedical evaluation by interview \& at least 1 of the following conditions apply:
- Not a woman of childbearing potential (WOCBP)
- WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 6 months after final study intervention administration.
- * Female participant must agree not to breastfeed starting at screening \& throughout the study period \& for 6 months after the final study intervention administration.
- * Female participant must not donate ova starting at screening \& throughout the study period \& for 6 months after the final study intervention administration.
- * Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period \& for 6 months after the final study intervention administration.
- * Male participant must not donate sperm during the treatment period \& for 6 months after the final study intervention administration.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05365581；登记信息更新于 2026-09-11。